ENTITY
Ascletis Pharma

Ascletis Pharma (1672 HK)

112
Analysis
Health Care • China
Ascletis Pharma is a fully integrated biotechnology company focused on the research, development, production, marketing, and sale of innovative pharmaceutical products. The company's marketed products include Ritonavir tablets, GANOVO®, and ASCLEVIR® for Hepatitis C, and it has a robust pipeline primarily in metabolic diseases, viral diseases, and oncology. Ascletis Pharma is headquartered in Hangzhou, China, and was founded in 2011.
more
bullish•BeOne Medicines
•08 Aug 2018 10:39

BeiGene (百济神州) Post-IPO: An ADR Tracker with Limited Near-Term Upside

BeiGene is the second biotech company to list in Hong Kong under amended listing rules that allow biotech companies which are yet to see a profit...

Logo
607 Views
Share
bearish•Ascletis Pharma
•06 Aug 2018 16:34

Ascletis Pharma (歌礼制药) Post-Listing: Thoughts on Liquidity and Bull Cases

Ascletis Pharma, the first biotech companies to list in Hong Kong without a profit under the amended listing rules, debuted last week with poor...

Logo
633 Views
Share
bearish•China Tower
•06 Aug 2018 04:50

Last Week in GER Research: Ascletis Pharma, China Tower, Pinduoduo, Beigene and CNFinance

Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight our sensitivity analysis for Ascletis...

Logo
1k Views
Share
bullish•Ascletis Pharma
•04 Aug 2018 12:12

Smartkarma: ECM Coverage Weekly Update (4 August 2018)

The Smartkarma ECM Team puts out a weekly update on the deals we have covered recently, along with updates for upcoming IPOs. Ascletis Pharma Inc...

Share
•03 Aug 2018 11:22

Hope Education (希望教育) IPO Trading - Appears Fully Priced for Now

Hope Education Group Co Ltd (1765 HK) quickly broke its IPO price after opening at HK$1.92 a share. There had been warning signs from its gray...

Share
x